je.st
news
Home
› Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies
Tetragenetics Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies
2016-01-06 06:05:47| drugdiscoveryonline Home Page
Tetragenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, announced recently a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states –such as pain and autoimmune disorders
Tags: development
program
partnership
discovery
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||